Anti-vegf Therapy
Anti-vegf Therapy - Related Videos
09:29
Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
0 Views •
Cited by 23 •
2016
Utilizing patient-derived tumors in a subcutaneous preclinical model is an excellent way to study the efficacy of novel therapies, predictive biomarker discovery, and drug resistant pathways. This model, in the drug development process, is essential in determining the fate of many novel anti-cancer therapies prior to clinical investigation.
08:27
Dynamic Adhesion Assay for the Functional Analysis of Anti-adhesion Therapies in Inflammatory Bowel Disease
0 Views •
Cited by 4 •
2018
Dynamic adhesion of immune cells to the vessel wall is a prerequisite for gut homing. Here, we present a protocol for a functional in vitro assay for the impact analysis of anti-integrin antibodies, chemokines or other factors on the dynamic cell adhesion of human cells using addressin-coated capillaries.
10:15
Isolation and Characterization of Neutrophils with Anti-Tumor Properties
0 Views •
Cited by 46 •
2015
Neutrophils play an important role not only in host defense against invading microorganisms, but are also involved in the immune surveillance of tumor cells. Here, we describe techniques related to the isolation of neutrophils with anti-tumor properties and methods for monitoring anti-tumor neutrophil function in vitro and in vivo.
04:21
An Assay to Detect Serum Anti-aquaporin-4 Immunoglobulin G
0 Views •
2025
The video demonstrates a cell-based assay for detecting anti-aquaporin-4 immunoglobulin G using a biochip containing untransfected cells and transfected cells expressing aquaporin-4. This method has applications in diagnosing neuromyelitis optica spectrum disorders, confirmed by strong green fluorescence on the biochip.
04:13
An Adjuvant Therapy in a Mouse Model with an Incompletely Resected Subcutaneous Tumor
0 Views •
2025
This video illustrates testing of adjuvant or additional therapy in a mouse model with incompletely resected subcutaneous tumors. The partially tumor-resected mouse is treated with an antibody targeting the anti-cytotoxic protein of T regulatory cells, potentially reducing tumor regrowth and suggesting effective adjuvant therapy.
FAQs
Anti-VEGF therapy can reduce retinal vascular dysfunction through two linked effects: limiting abnormal vessel growth and decreasing fluid leakage associated with increased vascular permeability. Therapeutic antibodies may bind VEGF directly, whereas related biologics can inhibit VEGF receptor pathways. Addressing both processes matters because disease-related retinal changes can involve excessive vessels, barrier leakage, or both.
Vascular permeability matters because increased permeability allows more fluid leakage from retinal blood vessels. Anti-VEGF treatment reduces this VEGF-associated effect, so its action is not limited to controlling abnormal vessel growth. The approach also addresses a change at the blood-retina barrier, linking molecular signaling to the goal of preserving visual function in retinal disease.
Blocking VEGF and inhibiting its receptor pathways intervene at related but distinct points in the same signaling system. An antibody can bind the signaling protein itself, while a related biologic can inhibit the receptor pathway that mediates its effects. Both approaches reduce abnormal vessel growth and fluid leakage, but they differ in the molecular target.
Intravitreal injection is the commonly described delivery route for anti-VEGF agents in retinal care. Its inclusion in clinical management reflects the use of biologic treatment in retinal disease, where VEGF-related vessel growth and fluid leakage are relevant. The intended clinical outcome is reduction of these abnormalities while helping preserve visual function.
Anti-VEGF therapy is used across several retinal disorders rather than being limited to one diagnosis. Key examples include neovascular age-related macular degeneration, diabetic macular edema, and retinal vein occlusion. Across these conditions, the shared therapeutic rationale is to counter VEGF-related abnormal vascular behavior and leakage, thereby helping preserve visual function.
Within neuroscience, the treatment provides an example of neurovascular signaling as a therapeutic target. Retinal disease can involve changes not only in vessels but also at the blood-retina barrier, and VEGF inhibition addresses both abnormal vessel growth and leakage-related signaling. This connects molecular vascular regulation with a functional visual outcome.